Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $104 to $106.
Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $104 to $106.